newsfilter
← Latest News
Business Wire·

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology ‑ EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance